Lupin Limited (NSE:LUPIN)
India · Delayed Price · Currency is INR | Market Cap | 970.94B |
| Revenue (ttm) | 247.51B |
| Net Income (ttm) | 43.25B |
| Shares Out | n/a |
| EPS (ttm) | 94.42 |
| PE Ratio | 22.45 |
| Forward PE | 22.83 |
| Dividend | 12.00 (0.57%) |
| Ex-Dividend Date | Jul 25, 2025 |
| Volume | 596,008 |
| Average Volume | 925,048 |
| Open | 2,127.00 |
| Previous Close | 2,119.10 |
| Day's Range | 2,111.10 - 2,146.90 |
| 52-Week Range | 1,795.20 - 2,402.90 |
| Beta | 0.35 |
| RSI | 63.76 |
| Earnings Date | Feb 6, 2026 |
About Lupin
Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India, the United States, and internationally. The company operates in two segments: Pharmaceuticals and Others. It engages in the drug discovery, development, production, marketing, and sale of various branded and generic formulations, biosimilars, over-the-counter and specialty drugs, and active pharmaceutical ingredients (APIs). The company also offers formulations for use in the therapeutic areas of anti-tuberculosis, diabetes management, cardiovascular, ... [Read more]
Financial Performance
In 2024, Lupin's revenue was 227.08 billion, an increase of 13.48% compared to the previous year's 200.11 billion. Earnings were 32.82 billion, an increase of 71.41%.
Financial StatementsNews
Lupin signs exclusive licensing agreement with Neopharmed for Plasil in Philippines and Brazil
Lupin Limited has announced a strategic move to strengthen its gastroenterology portfolio by entering into an exclusive licensing agreement with...
Lupin receives positive CHMP opinion for biosimilar ranibizumab Ranluspec in Europe
Lupin Limited has achieved a significant regulatory milestone after the Committee for Medicinal Products for Human Use (CHMP) of the...
Lupin receives US FDA EIR with VAI classification for Nagpur injectable facility
Lupin Limited on Tuesday announced that it has received the Establishment Inspection Report (EIR) from the United States Food and...
Lupin gets SBTi Validation for emission reduction targets across all emission scopes
Global pharmaceutical major Lupin Limited has achieved a significant sustainability milestone with its greenhouse gas (GHG) emission reduction targets receiving...
Lupin subsidiary forms long-term strategic alliance with PolyPeptide Group to strengthen global peptide supply chain
Lupin Manufacturing Solutions (LMS), a subsidiary of pharma giant Lupin Limited, has entered into a long-term strategic alliance with PolyPeptide...
Lupin receives U.S. FDA tentative approval for generic Siponimod tablets
Lupin Limited announced that it has secured tentative approval from the United States Food and Drug Administration (U.S. FDA) for...
Lupin signs exclusive licensing agreement with Valorum Biologics for biosimilar Armlupeg in the US
Lupin Limited has entered into an exclusive licensing agreement with U.S.-based biosimilar specialist Valorum Biologics for the commercial rollout of...
Lupin gets U.S. FDA Approval for Biosimilar Armlupeg
Lupin Limited has scored a major global milestone with the U.S. FDA clearing its new product Armlupeg™, a biosimilar version...
Lupin’s Nagpur Unit-1 clears USFDA Pre-Approval inspection with zero observations
Lupin Limited has confirmed that the US Food and Drug Administration has completed a product-specific Pre-Approval Inspection at the company’s...
Lupin unveils dedicated oncology block at Vizag to boost global CDMO capabilities
Mumbai, November 12, 2025: Lupin Manufacturing Solutions (LMS), a wholly owned subsidiary of Lupin Limited, has inaugurated a dedicated oncology...
Lupin share: Morgan Stanley maintains equalweight, Jefferies buy; brokerages see up to 16.8% upside on strong US business and margin guidance
Shares of Lupin Ltd remain on analysts’ radar after global brokerages Morgan Stanley and Jefferies maintained their positive stance on...
Lupin Ltd (BOM:500257) Q2 2026 Earnings Call Highlights: Record Revenue and Strategic Growth ...
Lupin Ltd (BOM:500257) Q2 2026 Earnings Call Highlights: Record Revenue and Strategic Growth Initiatives
Lupin’s Pune Bioresearch Centre clears US FDA inspection with zero observations
Global pharmaceutical major Lupin Limited announced that the U.S. Food and Drug Administration (US FDA) has successfully completed an onsite...
Q2 2026 Lupin Ltd Earnings Call Transcript
Q2 2026 Lupin Ltd Earnings Call Transcript
Lupin launches Authorized Generic Version of Ravicti Oral Liquid in the U.S.
Global pharma major Lupin Limited has announced the launch of an authorized generic version of Ravicti® (Glycerol Phenylbutyrate) Oral Liquid,...
Lupin launches strategic partnership program to expand reach of PrecisionSphere long-acting injectable platform
Lupin Limited has announced an exciting new partnership program to help more companies benefit from PrecisionSphere™, its long-acting injectable (LAI)...
Lupin shares rally over 3% after announcing $250 million investment in new manufacturing plant
Lupin Limited shares surged over 3% following the company’s announcement of a major expansion in the United States. The pharmaceutical...
Lupin launches Rivaroxaban for Oral Suspension in the US
Lupin Limited has announced an exciting new launch in the United States: Rivaroxaban for Oral Suspension, 1 mg/mL. This medicine is bioequivalent to Xarelto® Oral Suspension, 1 mg/mL from Janssen Phar...
Lupin shares jump over 3% after receiving U.S. FDA approval for Rivaroxaban for Oral Suspension
Lupin Ltd. shares rose over 3% in early trade after the company announced that it has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA)...
Lupin secures U.S. FDA approval for Rivaroxaban for Oral Suspension
Lupin Limited has recently informed exchanges that the company received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Rivaroxaban...
Lupin subsidiary Nanomi B.V. to acquire VISUfarma B.V. for €190 million
Lupin Limited has informed the exchanges that its wholly owned subsidiary in the Netherlands, Nanomi B.V., has entered into a definitive agreement to acquire VISUfarma B.V., a specialty pharmaceutical...
Lupin shares edge higher after tentative US FDA approval for HIV drug generic
Shares of Lupin Ltd edged up on Thursday, September 25, trading 1.34% higher at ₹2,017.50 apiece, after the company announced a key regulatory milestone. The global pharma major has received tentative...
Lupin gets tentative USFDA approval for HIV treatment drug
Global pharmaceutical company Lupin Limited has received tentative approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Bictegravir,...
Lupin’s Pune Biotech facility receives four observations in U.S. FDA Pre-Approval inspection
Lupin Limited, one of India’s leading pharmaceutical companies, announced that the U.S. Food and Drug Administration (FDA) recently conducted a product-specific Pre-Approval Inspection at its Pune Bio...
Lupin receives U.S. FDA nod for Lenalidomide Capsules
Lupin Limited has exciting news for patients and investors alike. The company announced that it has received approval from the U.S. Food and Drug Administration (FDA) for its Lenalidomide Capsules in ...